pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Firmagon
drug
save

degarelix acetate

Marketedupdated 3mo ago
by Ferring Pharmaceuticals Inc
Approved
community read0 votes

indications

investigational
Prostate Cancer

all catalysts(0)

nothing on the calendar yet

Trials studying degarelix acetate

  • phase3Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracersrecruitingn=493
  • phase2Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RPunknownn=202
  • —Effectiveness and Safety of Firmagon®completedn=676

Patent cliff

source: FDA Orange Book
first barrier falls
Feb 10, 2029
~2.5 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (18)

  • Apr 27, 2032method-of-use (U-1895)US 10695398
  • Apr 27, 2032method-of-use (U-1895)US 10695398
  • Apr 27, 2032method-of-use (U-1978)US 11766468
  • Apr 27, 2032method-of-use (U-1978)US 11766468
  • Apr 27, 2032method-of-use (U-1978)US 11826397
  • Apr 27, 2032method-of-use (U-1978)US 11826397
  • Apr 27, 2032method-of-use (U-1895)US 9415085
  • Apr 27, 2032method-of-use (U-1895)US 9415085
  • Feb 20, 2029method-of-use (U-1978)US 125148982.5y
  • Feb 20, 2029method-of-use (U-1978)US 125148982.5y
  • Feb 20, 2029method-of-use (U-4417)US 125333872.5y
  • Feb 20, 2029method-of-use (U-4417)US 125333872.5y
  • Feb 10, 2029method-of-use (U-1978)US 107297392.5y
  • Feb 10, 2029method-of-use (U-1978)US 107297392.5y
  • Feb 10, 2029method-of-use (U-1978)US 109738702.5y
  • Feb 10, 2029method-of-use (U-1978)US 109738702.5y
  • Feb 10, 2029method-of-use (U-1978)US 95793592.5y
  • Feb 10, 2029method-of-use (U-1978)US 95793592.5y

News(0)

no news has mentioned this drug yet

brand
Firmagon
generic
degarelix acetate
indication
Metastatic Prostate Cancer
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 34m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?